Every three years the Federal Office of Public Health (FOPH) reviews the reimbursement conditions and, more specifically, the prices of the medicines in the list of specialities covered by the compulsory health insurance (OKP). The medicines are split into three equal groups, containing…
Today Global Pricing Innovations (GPI) reports that it has validated an analytical method for forecasting new drug price potential during early stage development, opening a pathway to digital transformation for teams engaged in pricing and market access. GPI has successfully forecasted prices…
Make sure you get in touch with our Experts to find out how you can optimise your commercial potential through data analytics. For more info, contact preeti.patel@globalpricing.com
Luxturna (voretigen neparvovec), a gene therapy developed by Novartis, received ‘considerable added benefit’ from G-BA, the German health technology assessment. Luxturna is a one-off treatment for vision loss in adults and children, caused by retinal dystrophy from mutations in both copies of…
New office expansion enables GPI to accelerate growth in software engineering, professional services and customer support. London, October 1st, 2019 Global Pricing Innovations (GPI), today announced the opening of its second UK office in Cambridge, UK which will help to strengthen the…
BeNeLuxA collaboration is a joint initiative on drug pricing and reimbursement between the governments of Belgium, The Netherlands, Luxembourg, Austria and Ireland, with the aim of giving smaller countries greater negotiating power in discussing drug pricing with international drug firms. The group was…
In April 2019, the Spanish government submitted its ‘Updated Stability Program for 2019-2022’ to the European Union, reiterating the commitment to keep the national healthcare expenditure to 6% of the GDP. New and continuing budget control measures targeting the pharmaceutical expense, which comprise 19%…
Roche announced on Thursday, August 29, that Tecentriq (atezolizumab) in combination with Abraxane (protein-bound paclitaxel) had been approved in Europe for patients with PD-L1-positive, metastatic triple-negative breast cancer (TNBC). The Tecentriq combination marks the first cancer immunotherapy regimen to be available in…
On 1st August 2019, Italy’s State-Regions Conference approved a decree to reform the pharmaceutical pricing system of the country. A press release issued by the Ministry of Health states that the ‘Price Decree’ changes the procedures for the negotiation of the price…
President Trump’s administration has proposed to create an International Pricing Index (IPI) model for Medicare Plan B, which could bring international reference pricing (IRP) to the United States. The proposed change would apply to physician-administered therapies (covered by Medicare Part B) but not…
Earlier this month, the Government of Canada announced the final amendments to the Patented Medicines Regulations which estimates to save Canadians around $13 billion in the next decade and lay the foundation for National Pharmacare. The most significant reform to the regulations since…
Amendments to the Pharmaceutical Law in Russia will take effect from June 2019 and will be completed by 1st January 2021. Medicines which are reimbursed in Russia are listed on the Essential Drugs List (EDL), in which there are currently 735 products,…
Only recently did FDA approve Zolgensma® (by AveXis, a Novartis company), a gene therapy costing 2.1$ million, making it the most expensive medicine in the history of pharma. Zolgensma®’s most compelling feature is that it is a ‘one-off’ treatment. It utilises a…
Learn how GPI’s ground-breaking new approach to early price setting and TPP optimisation can quantify the value of your product, predict payer response and forecast price potential. Obtain unbiased, rapid insights in days, not months, saving you time and resources.
The retail prices of Pfizer’s leukaemia drug Bosulif (bosutinib) were cut by 13% in Germany on 1 June. This is likely a result of recent price negotiations with GKV-Spitzenverband payer group. Per AMNOG procedure, the negotiations were triggered by Bosulif losing its…
New pharmaceutical pricing rules were approved this past April in Kazakhstan. The new price control measures extended their scope from medicines within the state procurement system to pharmaceutical products sold in private marketing channels, such as in wholesale and pharmacies. In addition,…
Earlier this month, the Malaysian Ministry of Health has approved the introduction of international reference pricing (IRP) to benchmark medicines prices and ‘expand access to expensive new medicines’. A ceiling price will be derived from the average of the three lowest prices…
International Reference Pricing (IRP) is constantly under the spotlight as an effective mechanism to regulate the prices of medical products. In the USA there was a concern to implement IRP in an effort to try and constrain the increased prices of drugs in…
By Alexandros Soumalevris, GPI Working towards Health Technology Assessment (HTA) harmonisation There have been calls for the European Union (EU) countries, the European Parliament and other interested parties initiated in 2016 to the European Commission, to work on strengthening EU cooperation…
Shivani Shah Business Analyst Joined GPI in May 2018 To finish up our Employee Spotlight series we have our Business Analyst Shivani Shah. Based in our Mumbai office, Shivani gave us a quick insight into her day to day…. What motivates…
Madhuri Chhatbar HR Manager Joined GPI in September 2018 Kicking off our Tuesday with our next employee spotlight – Madhuri Chhatbar. Madhuri is our HR manager out in our Mumbai office and plays a crucial part not only with our employees but…
Pramod Mali Senior Business Analyst Joined GPI in February 2018 Our Employee Spotlight for this week focuses on Pramod Mali. Pramod is one of our superstar Senior Business Analysts in our office in Mumbai. Our HR manager Madhuri managed to catch Pramod…
By Alexandrosz Czira and Henrike Granzow Finding the right price in a cost-constrained global healthcare environment Needless to reiterate that costs of healthcare continue to increase. Some of the main drivers behind this trend are the development costs of novel and efficacious medicines…
Popat Bankar Business Analyst Joined GPI Mumbai in January 2017 Up this week in our Employee Spotlight Series is our Business Analyst – Popat Bankar. Popat is apart of our fantastic team of analysts based in our office out in Mumbai. Popat sat…
Tom Brockbank Consultant Joined GPI in May 2018 This weeks Employee Spotlight focuses on Tom Brockbank. Tom is a part of the core consultancy team based in our London office, whom help to guide our clients consulting requests on a daily basis….
Alexandrosz Czira Manager Joined GPI in September 2018 Global Pricing Innovations wouldn’t be the smart & fun company it is without our talented staff. So we decided to give you a little insight into some of the amazing employees who help…
We are full steam ahead here at Global Pricing Innovations, with a fantastic productive start to 2019! Due to our continued growth & expansion, we are still actively recruiting for the below list of roles: Pricing and Market Access Consultants Director – Web…
By Tom Brockbank, Henrike Granzow and Alexandrosz Czira, GPI Current treatment options and target indications Malignant melanoma is the most lethal form of skin cancer1. In the UK approximately 15,400 new cases occur per year, and since the early 1990’s the incidence…
Fertile ground for cross-border cooperation Even with pan-European EMA approval, pricing is still a country-level issue, with national governments, regional or local stakeholders and pharmaceutical companies being responsible for engaging in price formalities such as negotiations on a bilateral basis. But the landscape…
Biosimilar launches of antineoplastic monoclonal antibodies represent a milestone in oncological care but also a new chapter in the application of biosimilars; introducing more prescribers, payers and stakeholders to the biological copies. Rituximab biosimilars came to the European market in 2017, while trastuzumab…
GPI LEAP creates a clear vision for the most ambitious talent by inspiring individuals from diverse backgrounds to come together, grow and succeed in an innovative and dynamic team. We are passionate about growing and developing a world-class, high-performing team of experts through…
Legal questions around the “Mischpreis” pricing approach are still hanging over sickness funds and manufacturers in Germany. The current price setting methodology as part of AMNOG negotiations take average weighted prices and considers the value and price potential across all indications and patient…
One of the advantages of working in a global consultancy and technology solutions firm such as Global Pricing Innovations (GPI), which specializes in pharmaceutical pricing, is the wide exposure one receives to the many different challenges across disease areas, companies, and geographies. This…
Global Pricing Innovations are hiring! We are looking for pharmacists and project managers to join our expanding London based team. Please contact us for further information or email your resume to careers@globalpricing.com.
Partners4Access (P4A), the orphan drug specialists, and Global Pricing Innovations (GPI), the pricing experts, are moving to larger premises in central London to account for expansion and growth. Aligned to their innovative thinking and approach with their pharmaceutical clients, the new premises are…
Global Pricing Innovations (GPI) has further strengthened its technology division with the addition of Mikhael Aktsyzniy Mikhael joins GPI from Accenture as Head of Technology and Development to continue GPI’s success providing powerful pharma pricing intelligence based business services to valued clients across…
By Pati Ladron, Global Pricing Innovations In the face of restricted budgets, payers worldwide are increasingly using Health Technology Assessments (HTAs) as a way of managing healthcare budgets by providing access to therapies that demonstrate robust clinical and economic effectiveness. HTAs are a…
GPI are hiring! We are looking for innovative, team-orientated individuals to fill a number of open positions. Pricing Analyst – Data analyst from a pharma/health economics background PMA Consultant – Experienced consultant with solid background in project management and pricing strategies and/or modelling…
Canada’s plan to revise reference basket In a bid to reduce medicine prices in Canada, the Canadian Minister of Health announced the revision of the reference basket for international reference pricing (IRP). Medicines prices in Canada are regulated by the federal government, through…
With the largest population in the Middle East and North Africa region, Egypt has attracted a strong presence from multinational pharmaceutical companies. However, current turmoil over drug shortages and drug price hikes underscores the volatility of a market characterised by high out-of-pocket spending….
By Preeti Patel and Sophie Schmitz on Oct 3, 2016 We analyze recent changes in Germany’s pharmaceutical legislation & implications for the industry. Germany is typically prioritized by the pharmaceutical industry: it remains a market with relatively high drug prices, offers extensive commercial…
Pati Ladron – Client Solutions Lead at GPI Published 6th July 2016 …
Brexit: in or out? If you have lived in the UK for the past year, or anywhere else in the world for that matter, you are probably very familiar with the term. As one of the biggest political decisions of the 21st century,…
The PR & MA environment is evolving at a fast pace and securing access at the right price remains challenging. Successful adaptation is the key to effectively succeed in this ever-changing world, however, most companies find adapting to change difficult. In this…
